The price of FibroGen Inc (NASDAQ:FGEN) shares last traded on Wall Street rose 0.36% to $0.39.
FGEN stock price is now 9.24% away from the 50-day moving average and -60.21% away from the 200-day moving average. The market capitalization of the company currently stands at $39.20M.
With the price target reduced from $4 to $2, BofA Securities Downgraded its rating from Neutral to Underperform for FibroGen Inc (NASDAQ: FGEN). , while ‘Stifel’ rates the stock as ‘Hold’
In other news, Adib Deyaa, Chief Medical Officer bought 22,123 shares of the company’s stock on Jun 12 ’24. The stock was bought for $25,884 at an average price of $1.17. Upon completion of the transaction, the Chief Medical Officer now directly owns 82,123 shares in the company, valued at $32027.97. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 07 ’24, CEO Wettig Thane bought 50,000 shares of the business’s stock. A total of $95,470 was incurred on buying the stock at an average price of $1.91. This leaves the insider owning 470,178 shares of the company worth $0.18 million. A total of 6.94% of the company’s stock is owned by insiders.
During the past 12 months, FibroGen Inc has had a low of $0.18 and a high of $2.93. The fifty day moving average price for FGEN is $0.35672 and a two-hundred day moving average price translates $0.986425 for the stock.
The latest earnings results from FibroGen Inc (NASDAQ: FGEN) was released for 2024-06-30. The company reported revenue of $46.33 million for the quarter, compared to $40.13 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 15.45 percent.
